Pharmas Want Verdict Axed To Settle IP, Antitrust Disputes

Law360 (May 22, 2019, 7:02 PM EDT) -- Pharmaceutical companies Amphastar, Sandoz and Momenta told a Massachusetts federal court that they have resolved their sprawling antitrust and patent battles over generic blood thinners, as long as the court agrees to nix Amphastar’s win in the patent case.

The settlement — announced Tuesday — would end Amphastar Pharmaceuticals Inc.’s antitrust suit alleging Sandoz Inc. and Momenta Pharmaceuticals Inc. boxed it out of the market for generic blood thinners. And it would wrap up Sandoz and Momenta’s intellectual property case against Amphastar over a method to analyze blood thinners, along with the related Federal Circuit appeal.

“The parties have each independently...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!